Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • New Therapeutic Targets in Cardiovascular Diseases (Upcoming)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116691

The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.

H ten Cate, K A Bauer, M Levi, T S Edgington, R D Sublett, S Barzegar, B L Kass, and R D Rosenberg

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by ten Cate, H. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Bauer, K. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Levi, M. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Edgington, T. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Sublett, R. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Barzegar, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Kass, B. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Find articles by Rosenberg, R. in: JCI | PubMed | Google Scholar

Published September 1, 1993 - More info

Published in Volume 92, Issue 3 on September 1, 1993
J Clin Invest. 1993;92(3):1207–1212. https://doi.org/10.1172/JCI116691.
© 1993 The American Society for Clinical Investigation
Published September 1, 1993 - Version history
View PDF
Abstract

The human coagulation system continuously generates very small quantities of Factor Xa and thrombin. Current evidence suggests that basal level activation of the hemostatic mechanism occurs via Factor VIIa-dependent activation of Factor X, but direct proof has not been available for the participation of tissue factor in this pathway. To examine this issue, we infused relatively high concentrations of recombinant Factor VIIa (approximately 50 micrograms/kg body wt) into normal chimpanzees and observed significant increases in the plasma levels of Factor IX activation peptide, Factor X activation peptide, and prothrombin activation fragment F1+2. Metabolic turnover studies with radiolabeled Factor IX activation peptide, Factor X activation peptide, and F1+2 indicate that elevated levels of the activation peptides are due to accelerated conversion of the three coagulation system zymogens into serine proteases. The administration of a potent monoclonal antibody to tissue factor, which immediately neutralizes function of the Factor VIIa-tissue factor complex in vitro, abolishes the activation of Factor X and prothrombin mediated by the infused recombinant protein, and also suppresses basal level activation of Factor IX and Factor X. The above results suggest that recombinant Factor VIIa functions as a prohemostatic agent by interacting with endogenous tissue factor sites, but definitive proof will require studies in hemophilic animals using relevant hemostatic endpoints.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1207
page 1207
icon of scanned page 1208
page 1208
icon of scanned page 1209
page 1209
icon of scanned page 1210
page 1210
icon of scanned page 1211
page 1211
icon of scanned page 1212
page 1212
Version history
  • Version 1 (September 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts